Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety monitoring of atorvastatin combined with hybomib in the treatment of hyperlipidemia
ChiCTR2400092594Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of atorvastatin and Hybutimibe in hyperlipidemia, sponsored by Tianjin Medical University General Hospital. Primary endpoints: Incidence of adverse reactions, Severity of adverse reactions and 1 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
atorvastatinHybutimibe
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on ChiCTR2400092594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092594.